M Guttman

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort
    Mark Guttman
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 19:49-53. 2004
  2. ncbi request reprint Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD
    M Guttman
    Centre for Addiction and Mental Health, Division of Neurology, Department of Psychiatry, University of Toronto, Ontario, Canada
    Neurology 56:1559-64. 2001
  3. ncbi request reprint Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study
    M Guttman
    Division of Neurology, Department of Medicine, and Dean s Office, University of Toronto, Toronto, Ontario, Canada
    Neurology 57:2278-82. 2001
  4. ncbi request reprint Burden of parkinsonism: a population-based study
    Mark Guttman
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 18:313-9. 2003
  5. ncbi request reprint Parkinsonism in Ontario: physician utilization
    M Guttman
    Division of Neurology, Department of Medicine, University of Toronto, OntarioCanada
    Can J Neurol Sci 29:221-6. 2002
  6. ncbi request reprint Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mol Psychiatry 4:26-32. 1999
  7. ncbi request reprint Striatal dopaminergic and serotonergic markers in human heroin users
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neuropsychopharmacology 24:561-7. 2001
  8. ncbi request reprint Brain serotonin transporter binding in non-depressed patients with Parkinson's disease
    M Guttman
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada
    Eur J Neurol 14:523-8. 2007
  9. ncbi request reprint Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders
    S J Kish
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Neurol 55:1299-304. 1998
  10. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort
    Mark Guttman
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 19:49-53. 2004
    ..Preventive measures and aggressive management of these conditions as outpatients may reduce the rates of hospitalization and improve the morbidity and mortality of PKM...
  2. ncbi request reprint Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD
    M Guttman
    Centre for Addiction and Mental Health, Division of Neurology, Department of Psychiatry, University of Toronto, Ontario, Canada
    Neurology 56:1559-64. 2001
    ..DAT changes could influence the response to therapy in PD...
  3. ncbi request reprint Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study
    M Guttman
    Division of Neurology, Department of Medicine, and Dean s Office, University of Toronto, Toronto, Ontario, Canada
    Neurology 57:2278-82. 2001
    ..PD was associated with increased mortality before levodopa therapy became available. There have been conflicting reports of PD mortality in the modern era...
  4. ncbi request reprint Burden of parkinsonism: a population-based study
    Mark Guttman
    Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 18:313-9. 2003
    ..We conclude that the substantially higher physician and drug costs as well as hospitalization rates compared with controls clearly suggest that parkinsonism is associated with large direct costs to society...
  5. ncbi request reprint Parkinsonism in Ontario: physician utilization
    M Guttman
    Division of Neurology, Department of Medicine, University of Toronto, OntarioCanada
    Can J Neurol Sci 29:221-6. 2002
    ..Patients with Parkinsonism have a progressive disorder requiring substantial expertise to manage effectively...
  6. ncbi request reprint Brain choline acetyltransferase activity in chronic, human users of cocaine, methamphetamine, and heroin
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mol Psychiatry 4:26-32. 1999
    ..Studies of cognitive and brain cholinergic status in high dose users of MA are warranted...
  7. ncbi request reprint Striatal dopaminergic and serotonergic markers in human heroin users
    S J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Neuropsychopharmacology 24:561-7. 2001
    ..Our data suggest that chronic heroin exposure might produce a modest reduction in dopaminergic and serotonergic activity that could affect motivational state and impulse control, respectively...
  8. ncbi request reprint Brain serotonin transporter binding in non-depressed patients with Parkinson's disease
    M Guttman
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada
    Eur J Neurol 14:523-8. 2007
    ..Further investigation will be required to establish whether SERT binding is more or less decreased in those patients with PD who also have major depressive disorder...
  9. ncbi request reprint Brain glyceraldehyde-3-phosphate dehydrogenase activity in human trinucleotide repeat disorders
    S J Kish
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Ontario, Canada
    Arch Neurol 55:1299-304. 1998
    ....
  10. ncbi request reprint Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
    Stephen J Kish
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada
    Brain 131:120-31. 2008
    ....
  11. pmc Replication of association between ELAVL4 and Parkinson disease: the GenePD study
    Anita L Destefano
    Department of Biostatistics, Boston University School of Public Health, 715 Albany Street, Crosstown Center, 3rd Floor, Boston, MA 02118, USA
    Hum Genet 124:95-9. 2008
    ..This replication of association with rs967582 in a third cohort further implicates ELAVL4 as a PD susceptibility gene...
  12. pmc Sepiapterin reductase expression is increased in Parkinson's disease brain tissue
    Jennifer E Tobin
    Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA 02118, USA
    Brain Res 1139:42-7. 2007
    ..While the association of SPR to PD is not strong enough to support that this is the PARK3 gene, this study further implicates a role for SPR in idiopathic PD...
  13. ncbi request reprint Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study
    Mei Sun
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Arch Neurol 63:826-32. 2006
    ..The PARK2 gene at 6q26 encodes parkin, whose inactivation is implicated in an early-onset autosomal recessive form of Parkinson disease (PD)...
  14. ncbi request reprint Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study
    Samer Karamohamed
    Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
    Mov Disord 20:1188-91. 2005
    ..None of the variants were found in the GenePD families. Our results suggest that other variants or genes account for the familial risk of PD within the GenePD study...
  15. ncbi request reprint Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment
    Mark Stacy
    Duke University Medical Center, 932 Morreene Road, Durham, NC 27705, USA
    Mov Disord 20:726-33. 2005
    ..The mean number of wearing-off symptoms reported by the 165 subjects indicating wearing-off on the clinical survey was 6.25, with tremor being the most common motor feature and tiredness the most common nonmotor feature...
  16. ncbi request reprint Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  17. ncbi request reprint Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
    Junchao Tong
    Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health, Toronto, Canada
    Ann Neurol 55:125-9. 2004
    ..The supersensitive dopamine D(1) receptors in both striatum and cerebral cortex in PD might compensate for dopamine deficiency, but could also contribute to long-term complications of levodopa therapy...
  18. ncbi request reprint Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease
    Paul S Fitzmaurice
    Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
    Mov Disord 18:969-76. 2003
    ....
  19. ncbi request reprint VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, B C, Canada
    Synapse 49:20-8. 2003
    ..This is in keeping with a role for VMAT2 in other cellular processes (i.e., sequestration and release from the cell of potential toxic products), in addition to its importance for the quantal release of monoamines...
  20. pmc Current concepts in the diagnosis and management of Parkinson's disease
    Mark Guttman
    Department of Medicine, University of Toronto, Ont, Canada
    CMAJ 168:293-301. 2003
    ..Surgical treatment is an option for a defined patient population...
  21. ncbi request reprint Brain proteasomal function in sporadic Parkinson's disease and related disorders
    Yoshiaki Furukawa
    Movement Disorders Research Laboratory, Centre for Addiction and Mental Health Clarke Division, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Ann Neurol 51:779-82. 2002
    ..Our brain data suggest that a systemic, global disturbance in the catalytic activity and degradation ability of the proteasome itself is unlikely to explain the cause of Parkinson's disease...
  22. pmc PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study
    Anita L Destefano
    Department of Neurology, Boston University Schools of Medicine and of Public Health, Boston, MA 02118, USA
    Am J Hum Genet 70:1089-95. 2002
    ....
  23. doi request reprint Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada
    J Neurosci 28:9850-6. 2008
    ..If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine...